Melphalan 200 mg/m does not increase toxicity and improves survival in comparison to reduced doses of melphalan in multiple myeloma patients.

Autologous stem cell transplantation (ASCT) conditioned with melphalan 200 mg/m (Mel200) is standard of care for young multiple myeloma (MM) patients. Lower doses of melphalan (MelRed) have been used to reduce toxicity, although data regarding their efficacy are not concordant. We retrospectively evaluated 313 MM patients receiving ASCT at Jena University Hospital between 2003 and 2017.